Figure 2.

Elevation of CD4+ T cell counts in peripheral blood of FL patients receiving R² compared to R‐CHOP. CD4⁺ T and CD8⁺ T cells were enumerated in peripheral blood mononuclear cells (PBMC) from 193 patients with follicular lymphoma (FL) at baseline and after 24 weeks of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP; n = 92) or rituximab and lenalidomide (R²; n = 101) therapy, using flow cytometry. (A) Absolute CD4⁺ T cell counts at baseline and 24 weeks. (B) Percentage change in CD4⁺ T cell counts from baseline to week 24 (W24) of R‐CHOP or R² therapy. (C) Absolute CD8⁺ T cell counts at baseline and 24 weeks. (D) Percentage change in CD8⁺ T cell counts from baseline to week 24 of R‐CHOP or R² therapy. Data are presented as median with interquartile range. *P < 0·05 by one‐way anova (for A and C); *P < 0·05 by Unpaired t‐test (for B and D).